Anti-HLA-C antibodies and uses thereof
AssigneeJanssen Biotech, Inc.
InventorsRyan Eberwine, Anne Fourie, Paul H. Kim, Carl L. Manthey, Hong Zhou
Life of this patent
Estimating the term…
Abstract
Anti-HLA-C6 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as autoimmune diseases.
Claims14
An isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, and a HCDR3, the light chain variable region comprising a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences of:
- a. SEQ ID NOs:
- 37, 38, 39, 64, 65, and 66, respectively;
- b. SEQ ID NOs:
- 40, 41, 42, 67, 68, and 69, respectively;
- c. SEQ ID NOs:
- 43, 44, 45, 70, 71, and 72, respectively;
- d. SEQ ID NOs:
- 46, 47, 48, 73, 74, and 75, respectively;
- e. SEQ ID NOs:
- 49, 50, 51, 76, 77, and 78, respectively;
- f. SEQ ID NOs:
- 52, 53, 54, 79, 80, and 81, respectively;
- g. SEQ ID NOs:
- 55, 56, 57, 82, 83, and 84, respectively;
- h. SEQ ID NOs:
- 58, 59, 60, 85, 86, and 87, respectively;
- or
- i. SEQ ID NOs:
- 61, 62, 63, 88, 89, and 90, respectively;
- wherein the antibody or antigen-binding fragment thereof binds HLA-C.
An isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, and a HCDR3, the light chain variable region comprising a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences of:
- a. SEQ ID NOs:
- 91, 92, 93, 118, 119, and 120, respectively;
- b. SEQ ID NOs:
- 94, 95, 96, 121, 122, and 123, respectively;
- c. SEQ ID NOs:
- 97, 98, 99, 124, 125, and 126, respectively;
- d. SEQ ID NOs:
- 100, 101, 102, 127, 128, and 129, respectively;
- e. SEQ ID NOs:
- 103, 104, 105, 130, 131, and 132, respectively;
- f. SEQ ID NOs:
- 106, 107, 108, 133, 134, and 135, respectively;
- g. SEQ ID NOs:
- 109, 110, 111, 136, 137, and 138, respectively;
- h. SEQ ID NOs:
- 112, 113, 114, 139, 140, and 141, respectively;
- or
- i. SEQ ID NOs:
- 115, 116, 117, 142, 143, and 144, respectively;
- wherein the antibody or antigen-binding fragment thereof specifically binds HLA-Cw6.
An isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, and a HCDR3, the light chain variable region comprising a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences of:
- a. SEQ ID NOs:
- 145, 146, 147, 172, 173, and 174, respectively;
- b. SEQ ID NOs:
- 148, 149, 150, 175, 176, and 177, respectively;
- c. SEQ ID NOs:
- 151, 152, 153, 178, 179, and 180, respectively;
- d. SEQ ID NOs:
- 154, 155, 156, 181, 182, and 183, respectively;
- e. SEQ ID NOs:
- 157, 158, 159, 184, 185, and 186, respectively;
- f. SEQ ID NOs:
- 160, 161, 162, 187, 188, and 189, respectively;
- g. SEQ ID NOs:
- 163, 164, 165, 190, 191, and 192, respectively;
- h. SEQ ID NOs:
- 166, 167, 168, 193, 194, and 195, respectively;
- or
- i. SEQ ID NOs:
- 169, 170, 171, 196, 197, and 198, respectively;
- wherein the antibody or antigen-binding fragment thereof binds HLA-C.
Dependencies are inferred from the claim text.